Mitochondria Encode a Potent Immune Peptide That Fights Bacteria and Programs Macrophages
MOTS-c, a 16-amino-acid mitochondrial peptide, acts as a host defense peptide—killing MRSA, shaping macrophage identity, and linking mitochondria to immunity.
Summary
Researchers at USC have discovered that MOTS-c, a microprotein encoded in the mitochondrial genome, functions as a bona fide host defense peptide (HDP). The 16-amino-acid peptide is amphipathic and cationic—hallmarks of antimicrobial peptides—and directly kills E. coli and methicillin-resistant Staphylococcus aureus (MRSA) by disrupting bacterial membranes. In a mouse peritonitis model, MOTS-c fully neutralized MRSA infection. In human monocytes, interferon gamma, LPS, and differentiation signals each upregulated endogenous MOTS-c. When applied during primary mouse monocyte-to-macrophage differentiation, MOTS-c reprogrammed cells toward enhanced bacterial clearance, altered metabolism, and distinct antigen-presentation and interferon-signaling transcriptomes. These findings establish MOTS-c as the first mitochondrial-encoded immune factor, expanding the known genome-encoded immune repertoire beyond the nucleus.
Detailed Summary
For decades, the immune system has been considered exclusively a product of nuclear gene expression. This study overturns that assumption by demonstrating that the human mitochondrial genome encodes a functional host defense peptide—MOTS-c (mitochondrial open reading frame from the 12S rRNA type-c)—a 16-amino-acid microprotein with direct antibacterial and immunomodulatory activity.
The rationale draws on endosymbiotic theory: mitochondria descend from ancient proteobacteria, and early proto-mitochondria likely encoded immune factors to manage the newly formed cellular partnership. Consistent with this evolutionary logic, the authors show that MOTS-c is structurally amphipathic and cationic, properties that define classical host defense peptides (HDPs) and enable membrane disruption of bacterial pathogens.
In vitro bacterial killing assays demonstrated that MOTS-c directly targets both gram-negative E. coli and gram-positive MRSA, partially through hydrophobic and cationic domain interactions with bacterial membranes. Mechanistic evidence for membrane disruption was provided via membrane permeability and structural assays. Crucially, in a mouse model of acute MRSA peritonitis, exogenous MOTS-c completely neutralized bacterial infectivity, establishing in vivo antibacterial efficacy.
On the immunomodulatory side, endogenous MOTS-c expression in primary human monocytes was induced by three distinct immune stimuli: interferon gamma (IFNγ), lipopolysaccharide (LPS), and monocyte-to-macrophage differentiation signals. This interferon linkage is particularly notable, placing MOTS-c within a well-established antimicrobial induction pathway. When exogenous MOTS-c was applied during primary mouse monocyte differentiation, the resulting macrophages exhibited a transcriptomically distinct profile enriched for antigen presentation and IFN signaling pathways, enhanced bacterial phagocytosis and clearance, and a shifted metabolic state compared to control macrophages.
These findings collectively position MOTS-c as a first-in-class mitochondrial-encoded HDP and suggest the immune system is co-encoded by both the nuclear and mitochondrial genomes—a paradigm shift with broad implications for antimicrobial drug development, immunology, and our understanding of mitochondrial biology in aging and disease.
Key Findings
- MOTS-c is the first mitochondrial-encoded host defense peptide, with amphipathic, cationic structure matching classical antimicrobial peptides.
- MOTS-c directly kills E. coli and MRSA by targeting bacterial membranes via hydrophobic and cationic domains.
- In a mouse peritonitis model, MOTS-c fully neutralized MRSA infectivity in vivo.
- IFNγ, LPS, and differentiation signals each upregulate endogenous MOTS-c in human monocytes, linking it to interferon-driven immunity.
- Exogenous MOTS-c during monocyte differentiation programs macrophages with enhanced bacterial clearance, altered metabolism, and distinct IFN/antigen-presentation transcriptomes.
Methodology
The study combined structural peptide chemistry analysis, in vitro bacterial killing and membrane disruption assays against E. coli and MRSA, and an in vivo mouse acute peritonitis model. Human primary monocyte and mouse primary monocyte-to-macrophage differentiation systems were used alongside transcriptomic profiling to characterize immunomodulatory effects of MOTS-c.
Study Limitations
The in vivo data are limited to a single acute peritonitis mouse model; efficacy in chronic infection or other pathogen contexts remains untested. The precise receptor or intracellular signaling pathway through which MOTS-c reprograms macrophage differentiation has not yet been fully characterized. Translational relevance of endogenous MOTS-c levels in human infection or immune disease settings requires clinical validation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: